Overview

Pharmacokinetics and Safety in Healthy Volunteers

Status:
Completed
Trial end date:
2019-11-04
Target enrollment:
Participant gender:
Summary
Investigate the pharmacokinetics, safety and tolerability of SCT630 and to establish pharmacokinetic similarity of SCT630 to adalimumab.
Phase:
Phase 1
Details
Lead Sponsor:
Sinocelltech Ltd.
Treatments:
Adalimumab